Chief Scientific Officer · Aclaris Therapeutics, Inc. · Aclaris Therapeutics, Inc. — Employee Stock Option (Right to Buy)
Side
A
Value
—
Shares
334.9K
Price
—
Executed
Feb 2, 2026
Disclosed
Feb 6, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Feb 2 executedFeb 6, 2026 disclosed
ACRS · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing+6 / 15
Disclosed 4 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Aclaris Therapeutics, Inc. — Employee Stock Option (Right to Buy)
Ticker
ACRS
Shares
334.9K
Price per share
$0
Execution date (reported)
Feb 2, 2026
Owned after transaction
334.9K shares
Days from execution to publication
4
What this establishes
Kolbeck Roland Wilhelm filed this Form 4 reporting a grant or award of ACRS on Feb 2, 2026. It became public on Feb 6, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Scientific Officer
Kolbeck Roland Wilhelmcik:0002076327
Issuer
Aclaris Therapeutics, Inc.cik:0001557746
Revision history · 0
No field has changed since this record was first ingested.
